key: cord-0848433-r8yjrutk
authors: Maraj, Ilir; Hummel, James P; Taoutel, Roy; Chamoun, Romy; Workman, Virginia; Li, Cindy; Tran, Lydia; DelVecchio, Alexander; Howes, Christopher; Akar, Joseph G
title: Incidence and Determinants of QT Interval Prolongation in COVID‐19 Patients Treated with Hydroxychloroquine and Azithromycin
date: 2020-06-02
journal: J Cardiovasc Electrophysiol
DOI: 10.1111/jce.14594
sha: 4b5f8dd2b43caf7a058043d99379ae34e6c589fc
doc_id: 848433
cord_uid: r8yjrutk

Combined use of hydroxychloroquine and azithromycin was globally adopted, in part due to paucity and high cost of alternative therapies. However the utility of these medications has been questioned; and thus safety becomes a major concern given clinical equipoise regarding efficacy. This article is protected by copyright. All rights reserved.

New Haven, CT 06520

Tel: 203-737-4716

Fax 203-785-6506

Email: joseph.akar@yale.edu Combined use of hydroxychloroquine and azithromycin was globally adopted, in part due to paucity and high cost of alternative therapies. However the utility of these medications has been questioned; and thus safety becomes a major concern given clinical equipoise regarding efficacy.

Both hydroxychloroquine and azithromycin continue to be administered in US clinical trials examining their potential role in prevention of infection, treatment of mild infection in ambulatory patients, and in combination with other medical regimens in treatment of patients with severe disease. These drugs also continue to be clinically utilized in hospitalized patients around the globe, often without continuous telemetry due to lack of resources. Concern regarding use of hydroxychloroquine without adequate rhythm monitoring in clinical trials has been recently expressed. 1 A review of clinicaltrials.gov at the time of submission of this correspondence reveals actively recruiting trials of combined hydroxychloroquine/azithromycin with or without additional COVID-19 therapies, for both ambulatory and hospitalized patients within and outside the US. The potential for hydroxychloroquine and azithromycin to cause QT prolongation is counterbalanced by very low risk of pro-arrhythmia in the general population, and emerging evidence of relatively low risk of Torsades de Pointes (TdP) in COVID-19 patients. 2, 3, 4, 5 Thus delineation of the determinants of significant QTc prolongation and proarrhythmic risk for hydroxychloroquine/azithromycin is very important, especially given mounting evidence of inefficacy in COVID-19 treatment.

This article is protected by copyright. All rights reserved.

We conducted a retrospective analysis of consecutive symptomatic patients who were hospitalized for COVID-19 infection and received treatment with combination hydroxychloroquine/azithromycin. This study was approved by the Yale University ms and/or absolute QTc > 500 ms. 6 Secondary outcomes included ventricular tachyarrhythmias (TdP, polymorphic VT or VF).

Demographic, clinical and laboratory characteristics were compared between patients who developed QTc prolongation compared to those who did not. Continuous variables are expressed as mean ± standard deviation (SD). Proportions were compared using the χ 2 test. Continuous variables were compared using the t-test for normally distributed data or the Mann-Whitney U test if non-normal. Statistical significance was defined as p<0.05. This article is protected by copyright. All rights reserved.

Unadjusted odds ratios (OR) were calculated separately for each potential predictor of significant QT prolongation using univariable logistic regression. Significant predictors (p<0.05) from univariable analysis were then used as covariates in a multiple logistic regression model to calculate adjusted odds ratios (aOR).

The cohort consisted of 91 patients (age 62.7±15.1 years, 44% females,). Excessive QTc prolongation occurred in 23% of patients receiving hydroxychloroquine/azithromycin, increasing from 43737 to 50441 ms. In 14% of the cohort, the QTc exceeded 500 ms. The baseline characteristics of those with and without significant prolongation are shown in Table 1 . Patients with excessive prolongation were generally older (age 70.0±15.1 vs 60.5±14.5, p=0.016), with more hypertension (58% vs 40%, p=0.045), renal insufficiency(52% vs 20%, p=0.006), coronary artery (33% vs 8%, p=0.01) and cerebrovascular disease (24% vs 3%, p=0.01). In addition they appeared to develop greater severity of disease with 10/21 (48%) requiring mechanical ventilation compared to 15/70 (21%) without significant QT prolongation (p = 0.03). 9/21 (43%) patients with excessive QT prolongation had baseline renal insufficiency or developed acute renal failure. An additional concurrent QT-prolonging medication was administered in 42% of patients. Among patients with excessive QT prolongation, a concurrent QT prolonging drug was used in 67% of patients versus only 34% in patients without excessive QT prolongation (p=0.01). Most was due to intravenous propofol, which was used in 48% of patients with excessive QT prolongation compared to only 19% of patients without (p=0.01).

Significant ventricular arrhythmias occurred in 2 patients. One patient had classic TdP ( Figure 1 ) and the second patient developed polymorphic VT that degenerated into VF in This article is protected by copyright. All rights reserved.

the setting of severe multisystem disease. Table 2 This article is protected by copyright. All rights reserved.

Although there is a high degree of collinearity between severity of illness, mechanical ventilation and propofol use, this only highlights the importance of considering the determinants of QTc prolongation in this very sick population. 

Clinical Trials and QT-Prolonging Prophylactic Therapy in Healthy Subjects: First, Do No Harm

Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients This article is protected by copyright. All rights reserved. Accepted Article Testing Positive for Coronavirus Disease 2019 (COVID-19)

Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit

The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation